2021-03-31-accounts

Company number: 7487432 Charity number: 1139869 Charity number Scotland: SCO44260

Sarcoma UK

Annual Report and Accounts For the Year Ended 31 March 2021

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

CONTENTS
	Page
Chair of Trustees’ Statement	3
Reference and Administrative Details	4
Report of the Trustees:	5 - 28
Objectives and activities
Achievements and performance
Future plans
Governance, structure and management
Financial Review
Statement of responsibilities of the trustees
Acknowledgements	29 - 31
Independent Auditor’s Report to the Members of Sarcoma UK	32 - 35
Financial Statements:	36 - 47
Statement of financial activities
Balance sheet
Statement of cash flows
Notes to the financial statements

2

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Chair of Trustees’ Statement

After seven years’ involvement with Sarcoma UK I was honoured to succeed Glyn Wilmshurst as Chair of Trustees in October 2020. Glyn played a pivotal role in the considerable progress we have seen over the last ten years and he’ll be a tough act to follow.

2020 marks the tenth anniversary of Sarcoma UK being formally established and although the COVID-19 pandemic slowed some of our progress it has made us a stronger and more resilient charity.

The pandemic presented Sarcoma UK with a number of challenges but we responded quickly:

• We increased our Support Line capacity by 50% to deal with the increased calls and emails; produced tailored information for sarcoma patients and their families; held online support groups and joined other charities to produce quick, consistent information in a fast-moving situation.

• We diversified our fundraising, tested new products and adopted accordingly. We held a successful Emergency Appeal and also brought together twenty rare and less common charities for a campaign we called 20for20.

• Like many organisations we cut budgets, furloughed staff, restructured and made redundancies, took pay cuts and downsized our office space.

However we were also committed to delivering against our objectives for the year. In 202021 we:

• Consulted on, developed and launched robust organisational and research strategies.

• Funded almost £700,000 worth of pioneering sarcoma research.

• Provided both an interim and final report on Early Diagnosis which has led to a number of pieces of work that will hopefully lead to sarcomas being diagnosed earlier.

• Raised much needed awareness of sarcoma and Sarcoma UK.

Supporters are the lifeblood of Sarcoma UK and the pandemic really has shown how important they are to our survival and continued progress.

The theme of the activity marking our tenth anniversary this year is ‘People Make Sarcoma UK’ - that is as true in 2021 as it was when we were established in 2011. I’m confident that, after a turbulent and challenging 18 months, by working together we will bounce back bigger and bolder than before.

Sharon Reid Chair of Trustees

3

Sarcoma UK Reference and Administrative Details For the year ended 31 March 2021

Reference and Administrative Details

Company number	7487432 (Limited by guarantee in England and Wales)
Charity number	England and Wales (1139869)
	Scotland (SCO44260)
Registered office	49-51 East Road, London N1 6AH
Trustees	Trustees, who are also directors under company law, who
	served during the year and up to the date of this report were as
	follows:
	.
	Glyn Wilmshurst (Chair - term of office ended October 2020)
	Sharon Reid (Chair from October 2020)
	Sarah Conneally
	Andy Eckles
	Professor Ian Judson
	Louisa Nicoll
	Michael Parry (appointed October 2020)
	Sam Patton
	Isla Robinson
	Anjula Thompson
	Johanne Vass
	Sam Whittam
	Russ Wilson (appointed March 2020)
Patron	Richard Whitehead MBE
Chief Executive	Richard Davidson
Company Secretary	Katy Drake and Karen Wines
Bankers	CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill, West Malling,
	Kent ME19 4JQ
	Lloyds TSB, National Clubs & Charities, PO Box 1000,
	BX1 1LY
Solicitors	Brahams Dutt Badrick French LLP, 24 Monument Street,
	London, EC3R 8AJ
Auditor	Sayer Vincent LLP
	Chartered accountants and statutory auditors
	Invicta House
	108-114 Golden Lane
	London EC1Y 0TL

4

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Objectives and Activities

Sarcoma UK is the only cancer charity in the UK focusing on all types of sarcoma.

Our vision

Our vision is a world where everyone affected by sarcoma cancer has the treatment, care and support they need.

Our mission

Our mission is to ensure everyone affected by sarcoma receives the best treatment, care, information and support available and to create the treatments of the future.

Our goals

1. More people will survive sarcoma.

2. More will be known about the causes of sarcoma.

3. Everyone affected by sarcoma will have access to the best treatment and care.

What we do

• Drive awareness of sarcoma cancer.

• Find answers through funding sarcoma research.

• Provide information and support to anyone affected by sarcoma cancer.

• Campaign for better treatments and to improve standards of care.

Sarcoma facts and figures

1. Sarcomas are uncommon cancers that can affect any part of the body, on the inside or outside, including the muscle, bone, tendons, blood vessels and fatty tissues.

2. Fifteen people are diagnosed with sarcoma every day in the UK. That’s about 5,300 people a year.

3. There are around 100 different sub-types of sarcoma.

4. A key symptom of sarcoma is a lump that is increasing in size, often quickly.

5. Sarcoma diagnoses now make up about 1.4% of all cancer diagnoses in the UK.

6. Sarcomas account for about 11% of childhood cancers and about 14% of cancers in teenagers.

5

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

1. The majority of people are diagnosed when their sarcoma is about the size of a large tin of baked beans (10cm).

2. Sarcoma survival rates have been very gradually increasing over the last two decades in the UK. The five-year survival rate for sarcoma is 55%.

Achievements and Performance

Priority 1: Initiate change to raise awareness and improve standards of treatment and care

What we said we would do:

1. Increase the visibility of sarcoma and how it impacts on individuals and families so the public are familiar with sarcoma and its signs and symptoms.

2. Influence sarcoma health services so that sarcoma patients receive timely and high quality treatment and care, from diagnosis through to end of life care.

1. Increase Awareness

Pushing for awareness of cancer symptoms through the pandemic

• Throughout the pandemic we joined charity partners for calls with NHS England and supported the #CancerHasn’tStopped NHS Campaign.

Sarcoma Awareness Week

• Sarcoma Awareness Week (29 June – 5 July) saw the launch of our interim report on early diagnosis as well as the formal launch of our organisational policy priorities.

2. Influence health policy to improve sarcoma specialised services

National Sarcoma Survey

• Working with Quality Health, we completed our analysis of the National Sarcoma Survey 2020 and launched a full report of our findings. Over 1000 people completed the survey, giving us a robust dataset.

Key findings:

• 79% of respondents had not heard about sarcoma before their diagnosis.

• Around a third of respondents (30%) took more than 6 months to receive an accurate diagnosis, with 17% waiting more than a year.

• 25% of respondents said that their diagnosis and treatment of sarcoma has severely negatively affected their overall mental health.

• 45% of patients said they were not given enough information when they were first diagnosed.

• Dr Rachel Taylor from UCL will write up these results as an academic journal article.

6

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Establishing organisational policy priorities

• As part of our work to establish Sarcoma UK as a policy influencer, we finalised 10 policy priorities for the organisation. These were formed following consultation with the sarcoma community and analysis of our National Sarcoma Survey, and can be split into three themes:

• Early diagnosis

• Access to the best possible treatment and care

• Access to psychological support

Early Diagnosis

• In September our early diagnosis policy report, Delays Cost Lives, was launched. This report was built on a strong evidence base, combining findings from a comprehensive literature review, the findings of the National Sarcoma Survey 2020, and direct input from patients, carers and healthcare professionals from across the diagnostic pathway.

• In launching Delays Cost Lives, we welcomed support from Jess Phillips MP, and secured media coverage in the Times and Yorkshire Evening Post in additional to good pick up from parliamentarians in Westminster and Holyrood.

• Building on from the launch of Delays Cost Lives, we established an Early Diagnosis Expert Steering Group to shape our work in this area and to support its implementation.

• Taking an initial focus on Health Professional Education, we formed a collaboration with Gateway C to produce a free, accredited sarcoma e-learning module for GPs, due to launch in 2021.

• We established a new partnership with the Bone Cancer Research Trust, working on medical student education. This included conducting a survey of medical students and hosting student projects that explored preferred modes of learning.

• Our Early Diagnosis work was presented verbally and in poster form at the British Sarcoma Group conference and was awarded the best poster prize.

Medicines

• In April 2020 we saw the first new drug made available to sarcoma patients since 2017, thanks to input from Sarcoma UK. Larotrectinib was approved in England by the Cancer Drugs Fund and NICE for the treatment of a small group of sarcomas that carry a specific genetic abnormality. This ‘histology independent’ treatment works based on tumour genetics rather than tumour location. This was quickly followed by entrectinib, a similar treatment focusing on the same gene fusion.

• We submitted evidence to the NICE appraisal of avapritinib, a targeted treatment for a small number of GIST patients. This first appraisal led to a negative decision but we continue to work with NICE and the pharmaceutical company to call for flexibility.

• We worked with Immedica, the pharmaceutical company behind trabectedin, and provided the patient perspective to support the appraisal of the treatment. After four appraisals across over a decade, the Scottish Medicine Consortium finally approved the treatment for routine use in large part thanks to the work of Sarcoma UK.

• We have led the rare cancer sector’s response to the NICE Methods and Processes Review, the results of which could impact which drugs are made available in the

7

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

future. Leading the work of Cancer 52, we sat on several internal NICE Task and Finish Groups and co-authored several papers and letters to NICE regarding how the Review could help improve access to medicines for rare cancers.

Data

• Thanks to previous lobbying on sarcoma data, the National Cancer Registration and Analysis Service (NCRAS) released new data covering 2013 – 2017 sarcoma incidence and route to diagnosis in England. We were also able to access data up to 2016 for Wales, and up to 2017 for NI and Scotland. Although this remains an area where more progress is needed, this data release represented a major step forwards in building a picture of sarcoma incidence and care in the UK and was used to inform our early diagnosis work and key messages.

• We also worked directly Sandra Strauss and Public Health England to build engagement around the ongoing sarcoma data project which aims to use national cancer data to improve outcomes for sarcoma.

Priority 2: Seek answers through research

What we said we would do:

1. Become a £1 million per year investor in sarcoma research.

2. Invest in sarcoma researchers of the future.

3. Identify transformational ‘blue skies’ research.

1. Become £1 million per year investor in sarcoma research

• The impact of the pandemic required us to make major cuts to budget across the board, but despite this we were able to protect research funding and invest £697,307 into high quality sarcoma research across six research grants.

• This brings our total investment to date into sarcoma research to £4.28 million.

Grants awarded in 2020/21

Searching for new therapies for undifferentiated pleomorphic sarcoma Professor Valerie Brunton, The University of Edinburgh – PhD studentship

£119,988

Undifferentiated pleomorphic sarcoma (UPS) is the most common subtype of soft tissue sarcoma. However, these cancers are very complex, meaning that there are very few treatment options. This PhD studentship project aims to develop better models of undifferentiated pleomorphic sarcoma and to test potential drugs in these models, bringing us closer to making effective treatments available.

Looking for new treatments for metastatic soft tissue sarcoma

Dr William English, The University of Sheffield – PhD studentship

£117,850

When soft tissue sarcoma spreads to other parts of the body, the lungs are the most common site. Sadly, fewer than 20% of these patients will survive beyond five years,

8

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

meaning that new treatments are urgently needed. In this project, based in the laboratory of Dr William English, a PhD student will use cutting edge laboratory methods to identify new treatments for soft tissue sarcoma that has spread to the lungs.

Epithelioid Sarcomas: Genomic, Transcriptomic and Methylation Analysis

Professor Adrienne Flanagan, Royal National Orthopaedic Hospital (RNOH)

£41,070

Epithelioid sarcoma is very rare, with no viable treatment options, and there is also little information available about how it develops. This project will analyse epithelioid sarcoma patients’ samples to fill this knowledge gap. This work builds on the Sarcoma UK-funded GeCIP project, a major study analysing the 1,600 sarcoma samples in the 100,000 Genomes Project to develop personalised medicine for sarcoma patients.

Translational studies in the TAPPAS trial for angiosarcoma

Dr Paul Huang, Institute of Cancer Research (ICR) – PhD studentship

£120,000

A trial exploring drugs to treat angiosarcoma (TAPPAS) was terminated early due to lack of treatment effect, but there were a small group of patients in the trial who did benefit longterm. Using blood and tissue samples from these patients, this PhD project will aim to predict which patients are most likely to benefit from drug treatment. The team will also explore if a non-invasive blood test can be used to monitor how well someone is responding to treatment.

EORTC STRASS II Trial: An international clinical trial exploring treatment options for retroperitoneal sarcoma patients

Mr Dirk Strauss, Royal Marsden NHS Foundation Trust

£50,000

Some subtypes of retroperitoneal sarcoma are particularly aggressive, with a high risk of death in the years after treatment, so there is a clear need for new and better treatments. The first trial of its kind, the multi-national EORTC STRASS II trial aims to investigate whether delivering chemotherapy to these high-risk sarcoma patients before surgery is more effective than the standard treatment of surgery alone.

Exploring genomic data to find gene networks and new treatments for liposarcoma patients Dr Zoë Walters, University of Southampton – Genomics Research Programme

£248,398

Dedifferentiated liposarcoma is a particularly aggressive sarcoma subtype, and current treatments can be ineffective, with debilitating side effects. This project is exploring new ways of treating dedifferentiated liposarcoma, by identifying specific genetic changes which can be targeted with drugs.

Contribution to the CovidSurg-Cancer Initiative

Mr Anant Desai

£5,000

CovidSurg is a collaborative global cohort study which seeks to look at the outcomes of surgery in patients who develop COVID-19. This is especially important for sarcoma patients where surgery is often the main treatment available and there are few alternative options.

9

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

CovidSurg is led by scientists at the University of Birmingham in the UK, and has now captured data from over 20,000 patients from across 707 hospitals in 72 countries.

2. Invest in sarcoma researchers of the future

• We continued our commitment to training sarcoma research leaders of the future, supporting a total of eight PhD students across 2020/21.

• We awarded three new PhD studentships, bringing our total investment in PhD studentships alone to over £1.3 million. These studentships were awarded to Professor Valerie Brunton, Dr Paul Huang and Dr Will English, exploring treatment options for a variety of sarcomas.

• Sarcoma UK’s funding also supports a PhD student working on Dr Zoë Walters’ project.

3. Identify transformational ‘blue skies’ research

• We continued our commitment to supporting state-of-the-art research projects, developing ideas to improve our understanding of sarcoma, and to drive further innovative sarcoma research.

• 2020/21 saw us award the third research grant via our Genomics Research Programme. This initiative aims to bring together the best minds and the latest technologies in sarcoma research, using data from the 100,000 Genomes Project to advance our understanding of sarcoma. Dr Zoë Walters’ work aims to bring us a step closer to a new and better treatment for dedifferentiated liposarcoma (further details are given above). This commitment brings Sarcoma UK’s total investment in sarcoma genomics to £750,000.

• We also contributed £5,000 towards a major International research initiative, COVIDSurg, which has now collected data from over 140,000 patients in 116 countries. The cancer component of COVIDSurg explored the safety of surgery during the COVID-19 pandemic for cancer patients, to help clinicians and patients make decisions about surgery during the pandemic. Findings from the study have been published in leading academic journals, including top-tier medical journal The Lancet, with Sarcoma UK acknowledged as a co-funder.

• Due to the impact of COVID-19, we scaled back our clinical research funding round to a smaller £50,000 fund, focussing on collaborative clinical research projects in areas of high strategic priority for Sarcoma UK. We committed this funding to the EORTC STRASS II clinical trial, an innovative study exploring whether chemotherapy is effective in treating retroperitoneal sarcomas (further details can be found above). This collaborative funding also represents another international research contribution for Sarcoma UK, with research taking place across Europe, Australia and North America. Sarcoma UK’s investment will provide vital support to the UK arm of the trial.

• We continued to fund previous research commitments – see sarcoma.org.uk for details.

• We continued to monitor the impact of our funded research portfolio. 2020/21 was a challenging year for the research community, with COVID-19 restrictions reducing access to laboratories and causing delays to projects, and many scientific conferences were also cancelled. Despite these challenges, we continued to see high-quality outputs from our funded research grants:

• 18 academic publications in peer-reviewed journals, including high-impact journals such as Nature and The Lancet

10

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

• 12 oral presentations at UK and international scientific meetings and conferences, including several at the 2021 British Sarcoma Group Conference

• 3 poster presentations at UK and international scientific meetings and conferences

Strategic Direction of our Research Programme

• We held a series of discussions with researchers and other charity funders to gather views on our future research strategy and priorities, and we analysed our grants to date and their impact. We also surveyed our patient and supporter community to gain their insight. Based on these combined inputs, we developed our new research strategy Finding Answers Through Research , which launched in January 2021.

• Key themes of the strategy include a renewed focus on patient involvement, supporting a broader and more balanced research portfolio, and working more in collaboration with other funders.

• We maintained an active engagement with the NCRI, attending and presenting at the sarcoma strategy day, and the dedicated funder’s meeting.

Priority 3: Support the sarcoma community and provide information

• What we said we would do:

• Become a sarcoma expert information provider of choice.

• Be the first port of call for support.

• Work in partnership with others.

1. Sarcoma expert information provider of choice

• Our information webpages dedicated to sarcoma sub-types collectively received 136,567 page views during the year. In total we sent out 4,353 information resources in total compared to 7,502 the previous year, with this decrease being attributed to the impact of the COVID-19 pandemic. Our Clinical Trials Hub Find a Trial webpages also received 3,790 page views in total during the year.

• We produced our first information resource targeted specifically at Health Professionals. Titled the “Guide to Sarcoma for Allied Health Professionals”, this resource was developed with input from a range of Allied Health Professionals and aims to showcase how best to support people with sarcoma through accessing services in the community.

• We developed and regularly reviewed our information on COVID-19 and what it means for sarcoma patients.

• We maintained our Clinical Trials hub webpages, regularly updating this content to provide an accurate directory of sarcoma trials recruiting in the UK.

• We developed new information production processes and underwent assessment by the Patient Information Forum (PIF), resulting in us being awarded the PIF TICK Quality Mark, which establishes that we are a Trusted Information Creator.

11

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

2. First port of call for support

• The Support Line maintained a reliable and consistent service despite the challenges of the pandemic, keeping the lines, emails inboxes and text chats open.

• In total the Support Line had 2,994 contacts from 667 individuals . This represents an increase in contacts of 4.5% compared to the previous year, but a decrease in the number of individuals by 11%.

• The three main reasons reported for contacting the Support Line were diagnosis, treatment and support.

• Contacts about worrying symptoms increased by a factor of three and contacts reporting a fear of recurrence increased by 40%.

• In October, the Support Line Team began a pilot direct referral project with the Swansea Sarcoma Team. Each newly diagnosed patient was given an option to be contacted directly by the Support Line and offered support. Following evaluation, this pilot was considered effective and beneficial, and so will be continued with Swansea and expanded out to a small number of other sites.

• Learnings from the Support Line were presented at the British Sarcoma Group conference and at the National Sarcoma Forum.

Working with Sarcoma Support Groups

• A series of meetings were held with Support Group leaders to present Sarcoma UK’s new strategy and to explore how Sarcoma UK can best support them in their work.

• Members of the Sarcoma UK staff team joined and presented at a number of virtual support group meetings.

3. Partnership working

• We began a partnership with Vine Health, who provide a mobile app that supports people through cancer treatment. The app now provides signposting to the Sarcoma UK website and to the support line. We have also condensed our information resources into 2,000 word articles that now appear in the Vine Health app library.

• We established a partnership with C the Signs, a digital platform that supports GPs to identify patients at risk of cancer at earlier stages.

• We linked with the Cooper Rice Branding Foundation and Sock it to Sarcoma to share our experience of setting up the support line and helping share our experiences to help them take forward their plans for a more coordinated approach to sarcoma referrals in Australia.

• We met with a sarcoma patient and a carer from Ireland who want to set up a similar charity and support network in Ireland. Again we shared our experience and knowledge to help them take forward their plans.

• We met and shared information with Young Lives vs Cancer in order for both charities to be able to sign post to each other and allow a more integrated approach to support for all those affected by sarcoma.

• We also linked with Bright Futures UK, again to share the workings of each of the charities and how we can offer different things to those affected by sarcoma.

• We have been liaising with Ovacome to share the working of each charity to benefit patients.

12

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Priority 4: Build a strong charity

Our achievements are only possible because of the energy and generosity of our fundraisers and donors. Our diverse philanthropic community includes patients, their family and friends, health professionals, charitable trusts and businesses. Their enthusiasm, loyalty and belief in Sarcoma UK are vital to ensure people affected by sarcoma have the support they need, and sarcoma researchers continue to move closer to finding effective treatments. In 2020/21, our income was £1,875,292. We express our deepest gratitude to everyone who has made a donation or helped to raise funds this year.

Highlights of the year included:

• 20for20: The 20for20 Challenge was a pioneering and ground-breaking fundraising campaign. Spearheaded by Sarcoma UK’s fundraising team, the collaboration bought together 20 rare and uncommon cancer charities to form one partnership. The 20 day challenge saw supporters do a wide range of activities from dressing up for 20 days to doing 20 different fitness challenges. A very successful element of the campaign was creating a strong relationship with the challenge sponsors Takeda UK, who then also agreed to remain headline sponsors for 2021. The £151,000 raised will protect the future of each of the charities involved. The challenge has changed the mind-set for our future working, as there were huge positives come from the spirit of togetherness, which was needed at a time of uncertainty. This made the fundraising campaign incredibly effective in terms of the amount raised, inspiring everyone to be involved again with the campaign.

• Virtual events: The pandemic caused a monumental disruption to Sarcoma UK’s fundraising calendar. In order to ensure our supporters had opportunities to fundraise for our charity, the fundraising team came up with innovative virtual events and challenges. Offerings included a mix of established events that went online only (The Great British Picnic and the Christmas Carol Concert) and new digital fundraising campaigns and events (such as The Big Lockdown Quiz and Going the Distance: Mount Kilimanjaro).

• The 2.6 Challenge was announced by the UK’s mass participation industry to replace the April London Marathon; the challenge was announced a week before it was launched giving very limited preparation time. Despite the quick-turnaround many existing and new fundraisers connect with the charity in so many creative and active ways. Our 2020 London Marathon runners took part in ‘what would have been marathon weekend’ and used the 2.6challenge to boost their sponsorship and previous London Marathon runners also took part to mark the occasion.

• The London Marathon continues to be our successful flagship fundraising event, despite the physical race being cancelled; the 83 runners raised £303,202.77 including gift aid. This is the most that has ever been raised through the marathon.

• Due to COVID-19 many of our events and community fundraising was cancelled or postponed. We took the difficult decision to run an emergency appeal in November and asked our supporters to help us to safeguard Sarcoma UK services for the future. Our supporters collectively donated £200,000 and we saw a 24% uplift in monthly donations to continue to help us in the future.

• Sarcoma UK received our first National Lottery Grant for £98,000 as part of the Foundation’s COVID-19 Emergency provision. The grant successfully funded three 13

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

• months of support and information salaries. Equally we received a large grant of £20,000 from the Postcode Neighbourhood Trust (supported by players of the People’s Postcode Lottery), £13,000 from GSK and £10,000 from the Robert Luff Foundation.

• Our relationship with independent equity research firm The Analyst went from strength to strength and their donation of £150,000 this year took the total amount they have donated to Sarcoma UK to almost £850,000 over the last ten years.

• Our Fundraising and Communication teams have been working closer than ever to support our fundraisers. In the summer of 2020, one of our fundraisers, Stacey Jones, chose to mark Sarcoma Awareness week with an embroidery raffle on her Instagram account. Sadly, on the day the winner was planned to be announced, her husband, Chris Jones, passed away. To support Stacey, the embroidery community on Instagram joined together and thirty-two artists raffled their work and together raised over £3,250.

• During this financial year we have had two new Group Funds set up to raise funds in memory of their loved ones. The Tom Makin Group Fund has been put together from the London Marathon fundraising from ‘Tom’s Team’ organised by Kirsty Makin. Towards the end of the financial year, the Becky Punton Group Fund was set up by Becky’s husband, Alasdair.

• Our Genomics Development Board rose to our financial challenges and proactively made personal donations and took on virtual event challenges.

• When Meliz St Clair (nee Yalchin) was diagnosed with epithelioid sarcoma, an uncommon type of soft tissue sarcoma in 2016, she refused to give up hope. Sadly, she died three years later in 2019, but not before she could share that hope for a better future with everyone affected by sarcoma. The money raised by her friends and family to help fund further treatment was donated to Sarcoma UK’s Genomics Research Programme. It was used to expand (or uplift) one of our current research projects GeCIPing Sarcoma: A UK-led initiative to personalise sarcoma treatment.

• We are grateful for the continued support from Gwen Owen Robinson over the past five years. Her yearly gifts have changed the face for sarcoma researchers. The pioneering project which she funded in 2016 has enabled 11 new PhD researchers in sarcoma. Mark Elms, Shadi Hames, Shirin Hanaei, Molly McNae and Sara Arfan all hold a Sayako Grace Robinson PhD Studentship and have been working for some of the most prestigious and well-regarded researchers in the sarcoma field. We feel immensely proud of the work underway.

At Sarcoma UK we aim for best practice in all our fundraising activities. Our fundraising approach is to build long-term, meaningful relationships with donors and fundraisers based on transparency, respect, and the clear demonstration of the value of their involvement. We are aware that some supporters may be vulnerable or go through periods of vulnerability and have documented measures in place to help identify and protect vulnerable people who are in contact with the charity.

Covid Recovery and building a strong foundation for physical and virtual events. Our Team shrunk during the pandemic, from 4.6 to 3.6 full time equivalents and the director time was split between fundraising and comms. As events start to recover we will need to adapt to the landscape.

14

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

We have been registered with the Fundraising Regulator since its inception and comply with the Code of Fundraising Practice. We have a complaints procedure where our donors can register complaints. We have received no complaints in the year through this channel. We do not use third-party agencies to fundraise on our behalf.

The Finance and Operations team achieved the following:

• Ensured that the whole organisation was GDPR compliant.

• Continued effectively supporting remote operations as there was no requirement to work from the office during this financial year.

• Supported and enabled a number of new virtual fundraising initiatives.

• Downsized our office space from 24 to 6 desks in December 2020.

• Engaged an external IT support company, Penelope, who provide day to day first line IT support.

15

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

----- Start of picture text -----
Awareness,
campaigns &
education Raising funds
16% 21%
Information & How we spend
support
your money
17%
Research
46%
----- End of picture text -----

----- Start of picture text -----
Gift Aid Legacies
2%
9%
Corporate donations
11%
Trusts & foundations
12%
How we raise
Investment
our money income
1%
Major giving
9%
Sarcoma UK
General donations
55% special events
1%
----- End of picture text -----

The above activities include 18% support costs and 2% governance costs, which have been reallocated to each activity (see notes to financial statements)

16

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Future Plans

In the coming year we will continue on our path towards achieving the objectives outlined in our strategy to 2025.

17

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Specifically in 2021-22 we will:

1. We will fund and support the next generation of sarcoma researchers and encourage networking and collaboration

2. Award Laboratory PhD studentships.

3. Relaunch our research workshops scheme, providing funding for conferences and events that bring together sarcoma scientists to forge and develop collaborations.

4. Create a student network to bring together Sarcoma UK-funded PhD students and build networks within the field.

5. We will combine our grant funding streams to increase flexibility and efficiency

6. Run a single open grant round, to include laboratory and clinical grants across PhD studentships, small grants and large grants. This will run in parallel to the Genomics funding round of £250k.

7. We will involve people affected by sarcoma in our research programme so that it is better informed by their experiences and priorities

8. Introduce a new patient review stage to our open grant round.

9. Recruit patients to join Research Advisory Committee (RAC) and Research Strategy Committee (RSC).

10. We will launch targeted calls for funding in priority areas of research

11. Run a £250,000 genomics funding round in parallel to the open grant round.

12. We will work more closely with the sarcoma research community to shape our research programme and priorities

13. Launch a Research Strategy Committee to steer our future strategic research investments and to reflect on the impact of our funding to date with a panel that includes patients, clinicians and researchers from within and beyond the sarcoma field.

14. We will collaborate with healthcare professionals to engage with the National Institute for Health and Care Excellence (around guidelines, appraisal of new drugs and to improve delays to diagnosis)

15. Proactively respond to relevant priority policy consultations reflecting UK practice and healthcare professional views.

16. We will facilitate networking and collaboration among healthcare professionals to encourage the sharing of best practice and service improvement ideas

17. Become a more collaborative member of the BSG by driving and supporting their policy work.

18. Facilitate the work of the Early Diagnosis Steering Group and working with the Chair to achieve maximum impact.

19. Improve sarcoma care through collaboration with the SAG Chairs group on the Service Specification for Sarcoma.

20. We will improve the quantity and quality of education on sarcoma for healthcare professionals

21. Collaborate with partners (including charities and healthcare professional networks) to increase the opportunities for medical professionals to receive sarcoma education.

18

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

1. We will work to improve referral pathways and improve quick access to scans

2. Undertake a research project to understand current referral pathways and how these can be improved.

3. We will influence UK governments, the NHS and other policymakers to improve how sarcoma is diagnosed

4. Maintain and grow our influence in Westminster so that that sarcoma patient needs are understood and prioritised appropriately.

5. Ensure we have the funds to support the priorities above

6. Aim to raise between £1,458,000 and £1,778,000.

7. Support our community-based fundraisers and deliver a programme of virtual events.

8. • Repeat the 20for20 challenge.

9. Deliver a successful Glitter Ball in March 2022.

10. Deliver a programme of events for our tenth anniversary year.

11. Submit approaches to a range of trusts and foundations as well as the BBC Appeal.

12. Host a James Bond pre-premiere screening an in-person major donor cultivation events including a Christmas Carol concert.

13. Create a strong, stable organisation with good governance, systems and processes

14. Review and update of management information to include project and KPI/ milestone reporting that better informs decision-making.

15. Derive IT and Finance Strategies to ensure that these functions continue to evolve to be able to support the rest of the organisation in its systems and processes.

16. Conduct a number of reviews to increase the efficiency of the team and processes.

17. • Review banking and investment arrangements.

18. Ensure all members of the RAC and RSC sign up to terms of reference and complete conflict of interest forms and rotate at the end of their terms.

19. Recruit and Induct new members to the Board.

20. Build a portfolio of professional photographs, contacts and case studies to be used through all aspects of Communications work.

21. Review of Connect and its distribution.

22. Scope implementation of new grant management software.

23. Ensure that we have a positive, skilled team with appropriate training and development

24. Refresh our staff handbook (with a focus on well-being), benchmarking staff salaries to market and the setup of a well-being group.

25. Review our training and development processes and develop a T&D plan.

26. Utilise an external firm for IT support.

27. Take forward our equality, diversity and inclusion group work.

28. Increase public awareness of sarcoma through higher profile and targeted campaigns

29. Invest in regular boosted posts or placed advertising.

30. Continue to increase research communications by regularly providing updates on research projects and also improving content by utilising patient view or case study to provide context for what this research means for the sarcoma community.

31. Upgrade the website structure to better suit current user needs as ascertained through a website audit and current pattern of usage.

32. Continue and build on prior YouGov polling to understand sarcoma awareness and opinions across the country by region and by socio-political/ ethnic group.

19

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Some of the activities listed here will only be possible if we achieve income at the higher end of the range detailed above.

The impact of COVID-19 on Sarcoma UK’s work

Like most charities COVID-19 had a large impact on Sarcoma UK’s income and work last year. Although financial planning is now easier than last year as more is known, it is still uncertain. To deal with this uncertainty we have developed three budgets for the coming year: high, medium and low. We monitor our income and expenditure very closely and report to our Board of Trustees on a monthly basis and reforecast regularly. Certain activities and expenditure are due to happen later in the financial year so that we can introduce, amend or postpone as necessary.

We regularly and consistently speak to the staff team to ensure that morale is high and they feel supported and engaged. In a recent survey, 100% of our staff felt that the organisation had responded well to the pandemic and felt supported by their line manager.

We are always looking to reduce costs and be as efficient as possible while remaining effective. Last year we vastly decreased our accommodation costs and will keep them under review this year.

Governance, Structure and Management

Legal Entity

Sarcoma UK is a charity registered in England and Wales with the Charity Commission on 17 January 2011, and registered as a charity in Scotland on 12 September 2013. Its governing documents are its memorandum and articles of association. Sarcoma UK is also a company limited by guarantee incorporated with Companies House on 10 January 2011.

Sarcoma UK is sole corporate Trustee of former charity The Sarcoma Trust.

Charitable Objectives

The objectives of the charity are: to promote and protect the physical and mental health of patients with bone and soft tissue sarcomas in the United Kingdom through the provision of information, support, education and practical advice to them, their families and their carers; the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; to advance the education of the general public in all areas relating to sarcoma.

Board of Trustees 2020/21

Glyn Wilmshurst – Chair until October 2020

Glyn co-founded the communications agency Touchline, which produces the publications, websites and branding of several governments as well as various international arts, trade, travel and sports organisations. Glyn was diagnosed with a myxoid liposarcoma in December 2010.

20

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Sharon Reid – Chair from October 2020

Sharon is a former Executive Director and Chief Operating Officer at Edelman, the world’s largest PR agency, and has worked in communications for the last 18 years.

Sarah Conneally

Sarah is former Head of Events & Visits at 10 Downing Street, having worked for both David Cameron and Theresa May. Sarah was a colleague of Chris Martin at 10 Downing Street and she led their working group during our charity of the year partnership in 2016. Sarah is now a director at the newly formed Commonwealth Summit Unit, part of the Cabinet Office.

Andy Eckles – Trustee with special interest in finance

Andy has 30 years’ experience in finance, as both an auditor and currently as Group Financial Controller at Huntswood, a company that provides specialist resourcing and consultancy services. Andy’s son, Tom, passed away from Ewing’s sarcoma in September 2015.

Professor Ian Judson

Ian has been treating patients with sarcoma for 25 years as Head of the Sarcoma Unit at the Royal Marsden until his retirement in 2016. He has conducted many clinical trials in this area, and was a founder member of the British Sarcoma Group, and President until 2015.

Louisa Nicoll

Louisa is a nurse with extensive experience in the delivery of oncological and specialist palliative care services. She is currently Ward Manager at a Sue Ryder hospice in Henleyon-Thames. Louisa’s husband was diagnosed with high grade osteosarcoma in March 2016.

Michael Parry

Michael is a Consultant Orthopaedic Surgeon at the Royal Orthopaedic Hospital specialising in orthopaedic oncology and primary and revision lower limb arthroplasty. His specialist interests are in orthopaedic oncology and lower limb arthroplasty, with a particular interest in the management of infected joint replacements.

Sam Patton

Sam Patton is the Director of Orthopaedics & Consultant Orthopaedic Surgeon at the Royal Infirmary of Edinburgh . Sam has a long history of sarcoma practice and has served as a panel member on our Research Advisory Committee. Among his relevant experience are positions including Oncology Editor for The Bone & Joint Journal (the premier UK based orthopaedic journal) and Lead Clinician, Scottish Sarcoma Network in 2007-2013.

Isla Robinson

Isla Robinson is a freelance Marketing Consultant (Director level) with over 15 years’ experience of local and global marketing, including as a lead member of the team for Campari UK. Isla brings her professional expertise to the Board alongside first-hand experience of Ewing’s sarcoma with which she was diagnosed in 2011. This was when Isla first discovered Sarcoma UK, and she has since found the charity to be a ‘key source’ of reliable information.

21

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

Anjula Thompson

Anjula qualified as a Solicitor in 1993. She worked in private practice for 10 years and thereafter as a legal officer in the voluntary sector before taking up her current role, in 2005 as a Deputy District Judge, adjudicating in Civil and family cases. Anjula is the wife of Sarcoma UK trustee Dave Thompson who sadly passed away in 2016.

Johanne Vass

Jo is a Sarcoma Advanced Nurse Practitioner, the lead for sarcoma nursing services and a key member of the South Wales Sarcoma Multi-Disciplinary Team. She was the first sarcoma specialist nurse to be appointed in South Wales in 2012.

Sam Whittam

Sam is a barrister working principally in the area of child protection and was called to the bar in 1995. In 2009, Sam lost her friend to sarcoma.

Russ Wilson

Russ is currently a Partner at Hall & Partners, one of the UK's leading Brand Strategy consultancies. Russ has a very personal experience of sarcoma, having had an osteosarcoma removed from his leg when he was in his 20s.

The Board continue to follow the Charity Governance Code, to manage and take responsibility for Trustee governance. The Board has two committees, the Nominations and Human Resources (NHR) Committee and the Governance, Risk and Finance (GRF) Committee. The Board have produced a detailed Charity Governance Code assessment document, which will be reviewed by the GRF Committee and presented to the Board annually.

Nominations and Human Resources Committee (NHR)

Responsible for HR and staffing issues, including staff remuneration. Responsibility for the renewal of tenure, recruitment and appointment of trustees is also delegated to the Nominations and Human Resources Committee who make recommendations to the Board of Trustees.

Members 2020/21:

• Sam Whittam (Chair)

• Louisa Nicoll

• Isla Robinson

• Russell Wilson

Governance, Risk and Finance Committee (GRF)

Responsible for overseeing governance, organisational risk and working with the Senior Management Team on finance. The Governance, Risk and Finance Committee make recommendations to the Board of Trustees.

• Ian Judson (Chair)

Members 2020/21:

22

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

• Andy Eckles

• Anjula Thompson

• Johanne Vass

Trustee Appointment and Induction

Sarcoma UK places a high value on having an informed and skilled Board of Trustees which guides the charity to achieve its ambitious goals.

Trustees serve a three-year term, after which they are eligible for re-election for a further three years.

New trustees are recruited in various ways, according to the skills sought by the Board. Vacancies are advertised in national charity media. through professional networks and via the charity’s website and networks. Potential trustees are invited to submit a formal application and attend an interview with the Nomination and Human Resources Committee.

All trustees receive the Trustee Handbook, setting out the role and responsibilities of

Sarcoma UK trustees, including the charity’s policies and procedures relating to governance. A Register of Trustees’ Interests is in place and updated annually.

All new trustees receive the governing document, strategy and business plan, published accounts and minutes of previous Board of Trustee meetings, Trustee Handbook, as well as Charity Commission guidance on effective governance. A formal induction programme is in place, where trustees spend time with the Chief Executive and the Senior Management Team. Trustees are subscribed to Governance publication and are encouraged to attend training and other events for charity trustees.

Organisational Structure

The Board of Trustees sets the strategic direction of Sarcoma UK and approves the main policies of the charity. It appoints and directs the Chief Executive, monitors performance and identifies and manages the major risks facing the charity. The Board meets four times a year.

The Board delegates responsibility for the running of the charity to the Chief Executive with clearly communicated and recorded executive limits. The Chief Executive is responsible and accountable for achieving Sarcoma UK’s strategic objectives and delivering the annual business plan. A Senior Management Team is in place to support the Chief Executive, providing leadership across key areas of the charity’s work, and ensuring delivery of the charity’s day-to-day work.

Due to the pandemic and uncertainty in what levels of income Sarcoma UK would be able to raise in 2020/21 a difficult decision was taken to restructure the senior management team from 6 to 4 members. Following a period of consultation, in November 2020 four SMT roles were made redundant (Communications Director, Director of Fundraising, Director of Research and Director of Information and Support) and two new roles were created (Director of Fundraising and Communications and Director of Research, Policy and Support).

23

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

From 1[st] November 2020, Sarcoma UK’s Senior Management Team consisted of:

• Chief Executive

• Director of Finance and Resources (Head of Finance and Resources during period of maternity leave)

• Director of Fundraising and Communications

• Director of Research, Policy and Support

Sarcoma UK has a policy for reviewing staff salaries, set out in the Staff Handbook. Staff salaries are reviewed annually by the Board of Trustees Nominations and Human Resources Committee, on behalf of the Board of Trustees, and benchmarked against voluntary sector pay surveys and inflation. The remuneration of senior management is covered under this policy.

The total number of staff employed at 31 March 2021 was 20 (including 7 part-time). The trustees are grateful to the staff team for the outstanding work they do on behalf of people affected by sarcoma.

Volunteers

The trustees recognise the valuable contribution made by volunteers to Sarcoma UK and wish to record their gratitude for this commitment. These include: members of Sarcoma UK’s Research Advisory Committee; sarcoma support group leaders; Sarcoma UK’s

Information Review Panel; Sarcoma UK’s Medical Advisory Group, individuals and families who have provided their stories for use as case studies; everyone who has undertaken fundraising and awareness-raising in their communities; everyone who has set up information stands or cheering stations at events; and everyone who has supported Sarcoma UK at events and activities throughout the year. In accordance with accepted practice, no amounts are included in the financial statements to reflect the value of work undertaken by volunteers.

Risk Assessment

To manage risk effectively, Sarcoma UK uses a risk assessment model. The model sets out the processes for identifying major strategic risks, assessing their likely impact and, where appropriate, the measures that need to be implemented to mitigate the risks. These risks are regularly reviewed by the Senior Management Team and the Trustee Governance Risk and Finance Committee.

In our risk assessment model, risks are categorised under the following headings: Governance, Financial, Operational, Environmental and External Factors, Compliance Risk, and Charitable Objectives.

The most significant current risk to the charity has been identified as the impact of the external environment on fundraising, in particular:

1. Change to fundraising regulations.

2. Public confidence in charities.

3. Uncertainty around Britain’s withdrawal from the EU and the possible economic impact.

24

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

To manage this risk, the following actions will be incorporated into the risk model:

1. Investment into new fundraising streams to spread the risk and establish greater diversity in fundraising sources and provide a more balanced income portfolio.

2. Continue to be transparent in our practices demonstrating our activities and impact.

3. Robust monitoring of monthly management accounts to identify changes in income patterns as early as possible.

The risk model has been reviewed by the trustees and they are satisfied that appropriate systems are in place to mitigate major risks.

Grant Making Policy

Sarcoma UK is a member of the Association of Medical Research Charities (AMRC), an organisation of the leading medical and health research charities in the UK. In accordance with AMRC best practices, Sarcoma UK is committed to ensuring the highest standards of accountability, balance, independence, rotation of expertise and impartiality in our research programme.

We work closely with our independent Research Advisory Committee, comprised of scientific and clinical experts across a broad range of disciplines, in setting a Research Strategy. We are flexible in the range of research grants we award, with no area of research given greater priority over another. Our funding decisions are made on the basis of the scientific quality of the studies proposed, on the advice of independent scientific experts. We hold annual calls for proposals, which are open competition and publicised on our website and to the sarcoma research community. Applications submitted are subject to a preliminary triage of their eligibility, and then undergo a rigorous external peer review process by sarcoma research experts, to identify the best quality projects.

Our Research Advisory Committee oversees the research grant rounds. All Research Advisory Committee members and external peer reviewers adhere to our Principles of Peer Review Policy, as well as declaring conflicts of interest in line with our Conflicts of Interest Policy. A conflict of interest results in exclusion from review and participation in funding decisions. The Research Advisory Committee considers all peer reviews, and then makes recommendations for funding to Sarcoma UK’s Board of Trustees, who approve the final grants to be awarded.

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

Working with Others

Sarcoma UK recognises that progress towards our goals is maximised when working collaboratively with others who share an interest in improving the lives of people affected by sarcoma. As the only UK charity focusing on all types of sarcoma, we aim to work collaboratively with the whole sarcoma community to achieve our vision for the future. In 2020/21, Sarcoma UK had collaborations with: the Association of Medical Research Charities

25

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

(AMRC); BMJ Learning; Boom Foundation (Northern Ireland); British Sarcoma Group; Cancer 52; National Cancer Registry and Analysis Service (NCRAS), Welsh Cancer Intelligence and Surveillance Unit, Information Services Division of the NHS National Services Scotland, N. Ireland Cancer Registry, GIST Support UK; National Cancer Research Institute (NCRI) sarcoma clinical studies group; NCRI James Lind Alliance Priority Setting Partnership – Living With and Beyond Cancer steering group; National Institute of Health and Care Excellence (NICE); National Sarcoma Forum (of specialist nurses); NHS England; Public Health England, Sarcoma Patients EuroNet; the Scottish Sarcoma Network; the network of sarcoma specialist centres – bone and soft tissue – in England, Wales and Northern Ireland; Bone Cancer Research Trust; the Children and Young People’s Cancer Coalition; and all the charities that formed part of our 20for20 campaign.

Financial Review

Income

Sarcoma UK has made excellent progress against its objectives for the year, successfully raising £1,875,292, a decrease of 31% from the previous year (2020: £2,709,071), but income is slightly higher than that received in 2018-19 (£1,863,535).

This reduction is due to both receiving several large one-offs in 2019-20 (£224k from START, an unexpected legacy of £270k for research into Osteosarcoma and £95k from Daisy Ellis’ GoFundMe campaign) and a decrease in amounts received from community and event-based fundraising as a result of the pandemic

The trustees wish to thank all donors for their invaluable support during the year, which is helping Sarcoma UK transform the lives of everyone affected by sarcoma.

Expenditure

To mitigate the reduction in income Sarcoma UK carefully reviewed planned expenditure throughout the year making savings were possible. Consequently, total expenditure decreased to £1,868,955 (2020: £2,485,626), a decrease of 25%, in particular:

• Grants awarded were reduced by £214,075 to £691,521

• A reduction in event participation costs of £166,368 due to cancellation or postponement of events.

• Very reduced staff travel, no attendance at conferences and reduced training expenditure meant other staff costs reduced by £46,551.

• Downsizing our office space from 24 to 6 desks from January 2021 and very little attendance at the office meant our office costs reduced by £27,122 for the year.

• A reduction in awareness and campaigning costs of £62,996. In 2019/20 we incurred expenditure on a National Sarcoma Survey and a Sarcoma Awareness Campaign.

Sarcoma monitors spending closely, employing the use of financial management and budgetary controls across the charity and expenditure on our charitable activities remained high at 78% of total expenditure.

26

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

We strive to keep the costs of raising money to a minimum. This year for every £1 spent on fundraising £4.64 was raised. This has increased from the prior year as we have seen a significant increase in our income.

A surplus of £6,337 (2020: £223,445) was made this year and increases total charity funds to £1,408,501 (2020: £1,402,164), of which £2,134 are restricted. The reserves policy is discussed below.

Reserves Policy

Sarcoma UK revised its reserves policy during 2020. The Board of Trustees now aim to maintain reserves at a level which equates to approximately nine months of operational costs including budgeted salary, rent and support costs. This is approximately £725,000 for the forthcoming year.

The total funds of the charity at 31 March 2021 were £1,408,501 of which £2,134 are restricted. This leaves a balance of £1,406,367 as unrestricted funds. The trustees have agreed to designate £100,000 of these unrestricted funds to our core research costs and £100,000 to our information and support service in 2021/22, £9,959 are tied up as fixed assets leaving a balance of £1,206,367, which exceeds the level required by the reserves policy £725,000. Remaining funds of £481,367 will be applied to furthering our mission to ensure everyone affected by sarcoma receives the best treatment, care, information and support available and to create the treatments of the future.

The reserves policy including designation of funds will be reviewed in 2022 to ensure it is adequate for the charity’s future operational needs.

Statement of responsibilities of the trustees

The trustees (who are also directors of Sarcoma UK for the purposes of company law) are responsible for preparing the trustees’ annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

• Select suitable accounting policies and then apply them consistently.

• Observe the methods and principles in the Charities SORP.

• Make judgements and estimates that are reasonable and prudent.

• State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements.

• Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

27

Sarcoma UK Report of the Trustees For the year ended 31 March 2021

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

• There is no relevant audit information of which the charitable company’s auditor is unaware.

• The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees at 31 March 2021 was 12 (2020:12). The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Auditor

Sayer Vincent LLP was re-appointed as the charitable company's auditor during the year and has expressed its willingness to continue in that capacity.

The trustees’ annual report has been approved by the trustees on 5 October 2021 and signed on their behalf by

Sharon Reid

Chair of Trustees

28

Sarcoma UK Acknowledgements For the year ended 31 March 2021

Acknowledgements

Patron Richard Whitehead MBE Founder Roger Wilson CBE Ambassador Jake Quickenden

Research Advisory Committee

Professor Jeremy Whelan (Chair), Professor of Cancer Medicine, University College London.

Professor Andrew Beggs, Reader in Cancer Genetics & Surgery, University of Birmingham.

Dr Sam Behjati , Group Leader at the Wellcome Sanger Institute. Consultant Paediatric Oncologist, Addenbrooke’s Hospital, Cambridge.

Dr Sara Booth, Honorary Consultant, Associate Lecturer, University of Cambridge Honorary Senior Lecturer at the Department of Palliative Care and Policy, King’s College London.

Dr Bernadette Brennan, Consultant Paediatric Oncologist, Royal Manchester Children’s Hospital.

Professor Susan Burchill, Professor of Adolescent and Paediatric Cancer Research, Leeds Institute of Cancer and Pathology, University of Leeds.

Dr Quentin Campbell Hewson, Consultant Paediatric Oncologist, Great North Children’s Hospital in Newcastle upon Tyne.

Dr Louise Carter, Senior Clinical Lecturer in Experimental Cancer Medicine, University of Manchester.

Mr Paul Cool, Consultant Orthopaedic & Oncological Surgeon, The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry.

Mr Anant Desai, Consultant General Surgeon, Queen Elizabeth Hospital, Birmingham. Professor Adrienne Flanagan, Professor of Musculoskeletal Pathology, University College London. Consultant Pathologist/Clinical Lead, Royal National Orthopaedic Hospital

Mr Craig Gerrand, Consultant Orthopaedic Surgeon, Royal National Orthopaedic Hospital.

Dr Paul Huang, Team Leader, Division of Molecular Pathology, Institute of Cancer Research.

29

Sarcoma UK Acknowledgements For the year ended 31 March 2021

Professor Ted Hupp, Principal Investigator and Professor of Cancer Research, University of Edinburgh.

Dr Christina Messiou, Consultant Radiologist, The Royal Marsden Hospital and Honorary Faculty at The Institute of Cancer Research.

Dr Sophie Postel-Vinay, Physician Scientist, Drug Development Department and U981 INSERM research unit, Gustave Roussy Cancer Campus.

Dr Karen Sisley, Senior Lecturer, University of Sheffield.

Dr James Spicer, Consultant in Medical Oncology, Guy’s and St Thomas’ Hospitals Co-lead of the King’s Experimental Cancer Medicine Centre, King’s College London.

Dr Sandra Strauss, Consultant Medical Oncologist, University College Hospitals London.

Professor Galina Velikova, Chair of Psychosocial and Medical Oncology, University of Leeds.

Dr Jayne Wood, Consultant in Palliative Medicine and Clinical Lead, Royal Marsden and Royal Brompton Hospitals London.

In addition, the following members joined our RAC on an ad-hoc basis, to provide additional expertise to support our Genomics research funding calls:

Dr Javier Alfaro , Group Leader, Computational Immunology and Immunotherapeutics, University of Toronto.

Dr Priya Chudasama , Group Leader, Precision Sarcoma Research, German Cancer Research Centre.

We are deeply grateful to all those that have supported us during the year with special thanks to:

Argus Media Limited Ascot Underwriting Ltd Beazley Management Ltd Becky Punton Fund Belron Ronnie Lubner Charitable Foundation Boom Foundation Capsicum Re Foundation Chris Martin Fund CMS Cameron McKenna LLP Crispa Charitable Trust Dave Thompson Fund

30

Sarcoma UK Acknowledgements For the year ended 31 March 2021

Footasylum Ltd Fortis in Arduis Fund Fred and Charlie Allen Charitable Trust GeeWizz Charitable Trust GlaxoSmithKline UK Limited Immedica Pharma La Marzocco NAB Europe Ltd Novartis Pharmaceuticals UK Limited Peel Hunt Peter Thompson Fund Postcode Neighbourhood Trust Quidco Rotary Club of Helston-Lizard Sainsbury's Bury St Edmunds Samuel Estates Sayako Grace Robinson Fund Steph Darling Fund Sylvia Aitken's Charitable Trust Takeda UK Limited Telegraph Media Group Limited The Analyst Research LLP The David Brownlow Charitable Foundation The Hunter Foundation The Jacob Maloy Osteosarcoma Trust The Malcolm Whales Foundation The Medlock Charitable Trust The Michael and Morven Heller Charitable Foundation The National Lottery Community Fund The Robert McAlpine Foundation The Will Charitable Trust Tom Eckles Fund Tom Makin Fund Whitaker Charitable Trust XLN Telecom Limited

Individuals who have provided professional support

Mark Gould (Director, The Systems Management Company) has provided valuable professional support and advice to Sarcoma UK on a pro-bono basis.

A huge thank-you to all our supporters.

31

Sarcoma UK Independent Auditor’s Report For the year ended 31 March 2021

Opinion

We have audited the financial statements of Sarcoma UK (the ‘charitable company’) for the year ended 31 March 2021 which comprise the statement of financial activities, balance sheet, statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

• Give a true and fair view of the state of the charitable company’s affairs as at 31 March 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended

• Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice

• Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended)

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on Sarcoma UK's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other Information

The other information comprises the information included in the trustees’ annual report other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our

32

Sarcoma UK Independent Auditor’s Report For the year ended 31 March 2021

responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

• The information given in the trustees’ annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

• The trustees’ annual report has been prepared in accordance with applicable legal requirements

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

• Adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

• The financial statements are not in agreement with the accounting records and returns; or

• Certain disclosures of trustees’ remuneration specified by law are not made; or

• We have not received all the information and explanations we require for our audit; or

• The directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the trustees’ annual report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the statement of trustees’ responsibilities set out in the trustees’ annual report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the

33

Sarcoma UK Independent Auditor’s Report For the year ended 31 March 2021

trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

Capability of the audit in detecting irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

• We enquired of management, which included obtaining and reviewing supporting documentation, concerning the charity’s policies and procedures relating to:

• Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance;

• Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud;

• The internal controls established to mitigate risks related to fraud or noncompliance with laws and regulations.

• We inspected the minutes of meetings of those charged with governance.

• We obtained an understanding of the legal and regulatory framework that the charity operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the charity from our professional and sector experience.

• We communicated applicable laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit.

• We reviewed any reports made to regulators.

• We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations.

• We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud.

34

Sarcoma UK Independent Auditor’s Report For the year ended 31 March 2021

• In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Noelia Serrano (Senior statutory auditor) 12 October 2021 for and on behalf of Sayer Vincent LLP, Statutory Auditor Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006

35

Sarcoma UK

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2021

Unrestricted £ 1,504,715 2,220	Restricted £ 368,357 -	2021 Total £ 1,873,072 2,220	Unrestricted £ 1,812,712 9,320	Restricted £ 887,039 -	2020 Total £ 2,699,751 9,320
1,506,935	368,357	1,875,292	1,822,032	887,039	2,709,071
403,208 670,237 274,584 189,693	- 187,644 40,362 103,227	403,208 857,881 314,946 292,920	656,002 318,112 312,586 345,192	543 795,882 30,302 27,007	656,545 1,113,994 342,888 372,199
1,537,722	331,233	1,868,955	1,631,892	853,734	2,485,626
(30,787) 1,437,154	37,124 (34,990)	6,337 1,402,164	190,140 1,247,014	33,305 (68,295)	223,445 1,178,719

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 15 to the financial statements.

36

Sarcoma UK

Balance sheet

Balance sheet	Balance sheet
As at 31 March 2021			Company no. 7487432
Note £ Fixed assets: 10 Current assets: 11 359,689 108,569 3,246,107 3,714,365 Liabilities: 12 1,115,390 13 14 15 200,000 1,206,367 Total unrestricted funds Cash and cash equivalents Short term deposits Tangible assets Total assets less current liabilities Restricted income funds Unrestricted income funds: Designated funds Total charity funds Debtors The funds of the charity: Creditors: amounts falling due within one year Net current assets Total net assets Creditors: amounts falling due after one year General funds		2021 £ 9,959	£ 422,189 215,967 2,758,356	2020 £ 13,289
		9,959 2,598,975		13,289 2,585,465
	3,714,365 1,115,390		3,396,512 811,047
	200,000 1,206,367		200,000 1,237,154
		2,608,934 1,200,433		2,598,754 1,196,590
		1,408,501		1,402,164
		2,134 1,406,367		(34,990) 1,437,154
		1,408,501		1,402,164

Approved by the trustees on 5th October and signed on their behalf by Sharon Reid

Sharon Reid Chair of Trustees

37

Sarcoma UK

Statement of cash flows

For the year ended 31 March 2021

Analysis of cash and cash equivalents Cash at bank and in hand Notice deposits (less than three months) Total cash and cash equivalents Loss on disposal Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year Change in cash and cash equivalents in the year Net cash provided by investing activities Net cash provided by operating activities Cash flows from investing activities: Interest received Purchase of fixed assets Transferred (to) short term deposits Net income for the reporting period (as per the statement of financial activities) Depreciation charges Interest Decrease in debtors Increase in creditors Sale of Fixed Assets Cash flows from operating activities:	£ £ 6,337 6,057 222 (2,220) 62,500 308,186 381,082 107,398 2,220 146 (3,095) 106,669 487,751 2,758,356 3,246,107 At 1 April 2020 £ 2,353,541 404,815 2,758,356 2021	£ £ 6,337 6,057 222 (2,220) 62,500 308,186 381,082 107,398 2,220 146 (3,095) 106,669 487,751 2,758,356 3,246,107 At 1 April 2020 £ 2,353,541 404,815 2,758,356 2021	£ £ 223,445 7,702 - (9,320) 126,959 590,465 939,251 (2,926) 9,320 - (4,517) 1,877 941,128 1,817,228 2,758,356 Cash flows As at 31 March 2021 £ £ 483,802 2,837,343 3,949 408,764 487,751 3,246,107 2020	£ £ 223,445 7,702 - (9,320) 126,959 590,465 939,251 (2,926) 9,320 - (4,517) 1,877 941,128 1,817,228 2,758,356 Cash flows As at 31 March 2021 £ £ 483,802 2,837,343 3,949 408,764 487,751 3,246,107 2020
	107,398 2,220 146 (3,095)		(2,926) 9,320 - (4,517)
			Cash flows £ 483,802 3,949
		487,751 2,758,356		941,128 1,817,228
		3,246,107		2,758,356
		At 1 April 2020 £ 2,353,541 404,815		As at 31 March 2021 £ 2,837,343 408,764
		2,758,356	487,751	3,246,107

38

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

1 Accounting policies

a) Statutory information

Sarcoma UK is a charitable company limited by guarantee and is incorporated in the United Kingdom. The registered office address (and principal place of business, if different from the registered office) is 49-51 East Road, London, N1 6AH.

b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

c) Public benefit entity

The charitable company meets the definition of a public benefit entity under FRS 102.

d) Going concern

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern. They have reviewed the cash flow forecast and budget in light of COVID-19 and still consider this to be the case.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

e) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably.

Income from revenue grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor’s intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is a treated as a contingent asset and disclosed if material.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

f) Donations of gifts, services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), volunteer time is not recognised so refer to the trustees’ annual report for more information about their contribution.

On receipt, donated gifts, professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

g) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

39

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

1 Accounting policies (continued)

h) Fund accounting

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

i) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

• ˜ Costs of raising funds relate to the costs incurred by the charitable company in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purpose

• ˜ Expenditure on charitable activities includes the costs of raising sarcoma awareness, funding research and providing information and support, all undertaken to further the purposes of the charity and their associated support costs

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

j) Grants payable

Grants payable are made to third parties in furtherance of the charity's objects. Single or multi-year grants are accounted for when either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and that any condition attaching to the grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

k) Allocation of support costs

Resources expended are allocated to the particular activity where the cost relates directly to that activity.

Support costs are those costs which do not in themselves constitute a charitable or fundraising activity, but are the central office functions necessary to support these activities. They include administration, finance, HR and office overhead costs.

Governance costs are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional and statutory requirements and include any costs associated with the strategic management of the charity’s activities.

Support and governance costs are re-allocated to each of the activities on the following basis which is an estimate, based on staff time, of the amount attributable to each activity:

˜	Raising funds	30%
˜	Research	19%
˜	Information and support	32%
˜	Awareness, campaigns and education	19%

l) Operating leases

Rentals payable under operating leases, where substantially all the risks and rewards of ownership remain with the lessor, are charged to the statement of financial activities on a straight line basis over the minimum lease term.

40

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

1 Accounting policies (continued)

m) Tangible fixed assets

Items of equipment are capitalised where the purchase price exceeds £250. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

• ˜ Fixtures and fittings 5 years ˜ Computer equipment 5 years

n) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

o) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

p) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

q) Pensions

The charitable company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charitable company in an independently administered fund. The pension cost charge represents contributions payable under the scheme by the charitable company to the fund. The charitable company has no liability under the scheme other than for the payment of those contributions.

2 Income from donations and legacies

Legacies Donated goods and services Donations and gifts	Unrestricted £ 1,467,883 36,832 - 1,504,715	£ 368,357 - - Restricted	2021 Total £ 1,836,240 36,832 - 1,873,072	Unrestricted £ 1,765,712 35,000 12,000	£ 877,039 10,000 - 887,039 Restricted	2020 Total £ 2,642,751 45,000 12,000
		368,357		1,812,712		2,699,751

41

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

3a Analysis of expenditure (current year)

Staff costs (Note 6) Other staff costs Research grants payable (Note 4) Research support (development scheme) Travel & subsistence Fundraising fees Fundraising materials Events, participation & publicity costs Fundraising appeals Donor relationship management PR & marketing Support services Awareness & campaigning projects Information services Office costs Office communication costs Membership subscriptions Trustees development, expenses & meeting costs Legal & professional Insurance Bank charges Depreciation & Loss on Disposal Support costs Governance costs Total expenditure 2021	Cost of raising funds £ 226,584 (102) - - - 27,297 3,833 14,001 10,807 71 - - - - - - 6,308 - - - - -	Charitable activities	Charitable activities	Charitable activities	Governance costs £ 24,418 7,250 - - - - - - - - - - - - - - 1,282 27 8,173 - - -	Support costs £ 187,868 14,745 - - 256 - - - - - - - - - 106,267 11,285 - - 12,818 2,837 323 6,204	2021 Total £ 868,359 24,849 691,521 - 377 27,297 3,833 14,001 10,807 71 48,530 7,321 10,932 2,802 106,267 11,285 10,321 27 20,991 2,837 323 6,204	2020 Total £ 855,623 71,399 905,596 11,006 14,783 28,676 25,813 180,369 17,491 6,798 72,192 12,859 73,898 13,235 133,389 19,979 7,808 4,148 19,510 2,728 624 7,702
		Research £ 90,917 1,001 691,521 - 121 - - - - - - - - - - - 2,226 - - - - -	Information and support £ 181,243 857 - - - - - - - - - 7,321 25 2,802 - - 102 - - - - -	Awareness, campaigns and education £ 157,329 1,098 - - - - - - - - 48,530 - 10,907 - - - 403 - - - - -
	288,799 102,141 12,268	785,786 64,364 7,731	192,350 109,450 13,146	218,267 66,648 8,005	41,150 - (41,150)	342,603 (342,603) -	1,868,955 - -	2,485,626 - -
	403,208	857,881	314,946	292,920	-	-	1,868,955	2,485,626

42

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

3b Analysis of expenditure (prior year)

Staff costs (Note 6) Other staff costs Research grants payable (Note 4) Research support (development scheme) Travel & subsistence Fundraising fees Fundraising materials Events, participation & publicity costs Fundraising appeals Donor relationship management PR & marketing Support services Awareness & campaigning projects Information services Office costs Office communication costs Membership subscriptions Trustees development, expenses & meeting costs Legal & professional Insurance Bank charges Depreciation Support costs Governance costs Total expenditure 2020	Cost of raising funds £ 252,525 3,088 - - 602 28,676 25,813 180,369 17,491 6,798 - - - - - - 3,786 - - - - -	Charitable activities	Charitable activities	Charitable activities	Governance costs £ 24,647 4,507 - - - - - - - - - - - - - - 1,495 4,148 7,920 - - -	Support costs £ 185,087 24,674 - - - - - - - - - - - 133,389 19,979 381 - 11,590 2,728 624 7,702	2020 Total £ 855,623 71,399 905,596 11,006 14,783 28,676 25,813 180,369 17,491 6,798 72,192 12,859 73,898 13,235 133,389 19,979 7,808 4,148 19,510 2,728 624 7,702
		Research £ 85,855 22,541 905,596 11,006 2,410 - - - - - - - - - - - 1,606 - - - - -	Information and support £ 174,377 6,133 - - 9,470 - - - - - - 12,859 1,227 13,235 - - 102 - - - - -	Awareness, campaigns and education £ 133,132 10,456 - - 2,301 - - - - - 72,192 - 72,671 - - - 438 - - - - -
	519,148 123,712 13,685	1,029,014 76,516 8,464	217,403 112,986 12,499	291,190 72,940 8,069	42,717 - (42,717)	386,154 (386,154) -	2,485,626 - -
	656,545	1,113,994	342,888	372,199	-	-	2,485,626

43

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

4 2022 2023 2024 2025 2026 2021 2020 £ £ - 80,389 - 34,130 34,249 34,371 17,250 120,000 120,000 - - - - - - 119,873 - - - - - - 236,479 5,000 - - - - 5,000 249,584 - - - - - - 116,374 20,708 14,646 14,646 - - 50,000 - - 64,311 96,577 87,510 - 248,398 - - 31,923 34,833 39,891 11,203 117,850 - - 30,994 36,448 38,432 14,114 119,988 - 41,070 - - - - 41,070 - 702,306 922,699 - (16,925) - (178) (36) - (10,749) - 691,521 905,596 5 2021 2020 £ £ 6,057 7,702 148 - (2,220) (9,320) 74,107 90,389 6,800 6,600 6 2021 2020 £ £ 736,783 740,593 17,536 - 73,428 73,430 31,699 30,500 8,913 11,100 868,359 855,623 No. No. 1 1 1 - Payment Schedule Full details of grant making activities are disclosed on page 8-9 of the report of the trustees. £90,000 - £99,999 Loss on disposal of fixed assets Staff costs were as follows: University College London Hospitals NHS Foundation Trust At the end of the year Grants to institutions: Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel Institute of Cancer Research Imperial College London University of Oxford University of Birmingham Royal National Orthopaedic Hospital University of Edinburgh (underspend) Newcastle Upon Tyne Hospital Audit University College London Hospitals NHS Foundation Trust University of Leeds University of Southampton Redundancy and termination payments Net income for the year Interest received Operating lease rentals: Auditor's remuneration (excluding VAT): This is stated after charging / (crediting): Depreciation Property Royal Marsden NHS Foundation Trust University of Sheffield University of Edinburgh University of Liverpool (underspend) £60,000 - £69,999 Grant making Employer’s contribution to defined contribution pension schemes Salaries and wages Social security costs Accrued holiday pay The following number of employees received employee benefits (excluding employer pension costs and national insurance contributions) during the year between:	2021 £ - 120,000 - - 5,000 - 50,000 248,398 117,850 119,988 41,070	2020 £ 80,389 120,000 119,873 236,479 249,584 116,374 - - - - -
	702,306 - - (36) (10,749)	922,699 (16,925) (178) - -
	691,521	905,596
	2021 £ 6,057 148 (2,220) 74,107 6,800	2020 £ 7,702 - (9,320) 90,389 6,600
	2021 £ 736,783 17,536 73,428 31,699 8,913	2020 £ 740,593 - 73,430 30,500 11,100
	868,359	855,623

The total employee benefits including pension contributions and national insurance of the key management personnel were £390,741 (2020: £363,336) incurred by 7 (2020: 8) employees.

The charity trustees were not paid or received any other benefits from employment with the charity in the year (2020: £nil). No charity trustee received payment for professional or other services supplied to the charity (2020: £nil).

Trustees' expenses represents the payment or reimbursement of travel and subsistence costs totalling £27 (2020: £3,646) incurred by 1 (2020: 14) members relating to attendance at meetings of the trustees. The costs shown in note 3 for trustees’ development, expenses & meeting costs also include costs relating to trustee meeting lunches, which are not direct trustee expenses relating to attendance at meetings of the trustees.

44

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

7 Staff numbers

Raising funds Information and support Support Research Awareness and campaigns	2021 No. 5 1 5 4 6	2020 No. 5 2 5 4 6
	21	22

8 Related party transactions

Sarcoma UK Trustees and close family personally donated and raised £12,628 (2020: £12,580).

9 Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10 Tangible fixed assets

Tangible fixed assets
Depreciation At the end of the year At the start of the year Net book value At the end of the year At the end of the year At the start of the year Additions in year Disposal Cost or valuation At the start of the year Charge for the year Disposal All of the above assets are used for charitable purposes.	Fixtures and fittings £ 29,520 - -	Computer equipment £ 32,586 3,095 (552)	Total £ 62,106 3,095 (552)
	29,520	35,129	64,649
	23,291 3,115 -	25,526 2,942 (184)	48,817 6,057 (184)
	26,406	28,284	54,690
	3,114	6,845	9,959
	6,229	7,060	13,289

11 Debtors

Grants payable: Creditors: amounts falling due within one year Accruals Other debtors Prepayments Other creditors Deferred income Trade creditors Taxation and social security 1 - 2 years 2 - 5 years Grants payable Creditors: amounts falling due after one year Accrued income	2021 £ 13 234,540 125,136	2020 £ 31,144 253,413 137,632
	359,689	422,189
	2021 £ 3,220 18,028 5,579 41,319 1,000 1,046,244	2020 £ 11,346 21,481 5,164 108,543 1,000 663,513
	1,115,390	811,047
	2021 £ 482,367 718,066	2020 £ 705,836 490,754
	1,200,433	1,196,590

12 Creditors: amounts falling due within one year

13 Creditors: amounts falling due after one year

45

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

14a Analysis of net assets between funds (current year)

Tangible fixed assets Long term liabilities Net assets at 31 March 2021 Net current assets	General unrestricted £ 9,959 2,396,841 (1,200,433)	Designated £ - 200,000 -	Restricted £ - 2,134 -	Total funds £ 9,959 2,598,975 (1,200,433)
	1,206,367	200,000	2,134	1,408,501

14b Analysis of net assets between funds (prior year)

Total restricted funds General funds Total restricted funds General funds Research Information and support Tangible fixed assets Net current assets Long term liabilities Net assets at 31 March 2020 Movements in funds (current year) Movements in funds (prior year) Total designated funds Designated funds: Sarcoma Trust Unrestricted funds: Total unrestricted funds Research Total funds Information and support Total designated funds Total funds Research Information and support Total unrestricted funds Information and support Awareness, campaigns and education Restricted funds: Sarcoma Trust Infrastructure development Awareness, campaigns and education Unrestricted funds: Designated funds: Research Restricted funds:	At 1 April 2020 £ 10 (35,000) - -	General unrestricted £ 13,289 2,420,455 (1,196,590)	Designated £ - 200,000 -	Restricted £ - (34,990) -	Total funds £ 13,289 2,585,465 (1,196,590)
		1,237,154	200,000	(34,990)	1,402,164
		Income and gains £ - 222,644 40,362 105,351	Expenditure and losses £ - (187,644) (40,362) (103,227)	Transfers £ - - - -	At 31 March 2021 £ 10 - - 2,124
	(34,990)	368,357	(331,233)	-	2,134
	100,000 100,000	- -	(100,000) (100,000)	100,000 100,000	100,000 100,000
	200,000	-	(200,000)	200,000	200,000
	1,237,154	1,506,935	(1,337,722)	(200,000)	1,206,367
	1,437,154	1,506,935	(1,537,722)	-	1,406,367
	1,402,164	1,875,292	(1,868,955)	-	1,408,501
	At 1 April 2019 £ 10 1,695 (70,000) - -	Income and gains £ - - 830,546 29,806 26,687	Expenditure and losses £ - (1,695) (784,046) (41,306) (26,687)	Transfers £ - - (11,500) 11,500 -	At 31 March 2020 £ 10 - (35,000) - -
	-	-	-	-	(34,990)
	- -	- -	- -	100,000 100,000	100,000 100,000
	-	-	-	200,000	200,000
	1,247,014	1,822,032	(1,631,892)	(200,000)	1,237,154
	1,247,014	1,822,032	(1,631,892)	-	1,437,154
	1,247,014	1,822,032	(1,631,892)	-	1,437,154

15a Movements in funds (current year)

15b Movements in funds (prior year)

46

Sarcoma UK

Notes to the financial statements

For the year ended 31 March 2021

Purposes of restricted funds:

Sarcoma Trust

These funds represent the amounts retained within the Sarcoma Trust after becoming a linked charity with Sarcoma UK.

Infrastructure Development

Expenditure against the fund relates to depreciation charges for the year, on assets purchased to develop the infrastructure of Sarcoma UK.

Research

These funds are to be used specifically towards research grants, as requested by the donor.

Information and Support

These funds are to be used specifically towards the provision of support and information for the sarcoma community, as requested by the donor.

Awareness, Campaigns and Education

These funds are to be used specifically towards raising awareness and improving standards of treatment and care, as requested by the donor.

Purposes of designated funds:

Research

These funds represent those designated by the trustees towards our core research costs in 2020/21. These core costs include research grants awarded and research management costs.

Information and Support

These funds represent those designated by the trustees towards our information and support service in 2020/21. These costs include the running of our support line service and production of patient information.

16 Operating lease commitments

The charity's total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods:

Less than one year	2021 2020 £ £ 5,763 23,051 5,763 23,051 Property	2021 2020 £ £ 5,763 23,051 5,763 23,051 Property	2021 2020 £ £ 207 828 207 828 Equipment	2021 2020 £ £ 207 828 207 828 Equipment
	5,763	23,051	207	828

17 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

47